HRP20151378T1 - Derivati kromena korisni u liječenju bolesti posredovane međudjelovanjem trc-nck - Google Patents
Derivati kromena korisni u liječenju bolesti posredovane međudjelovanjem trc-nck Download PDFInfo
- Publication number
- HRP20151378T1 HRP20151378T1 HRP20151378TT HRP20151378T HRP20151378T1 HR P20151378 T1 HRP20151378 T1 HR P20151378T1 HR P20151378T T HRP20151378T T HR P20151378TT HR P20151378 T HRP20151378 T HR P20151378T HR P20151378 T1 HRP20151378 T1 HR P20151378T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- substance
- formula
- independently represents
- ring
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 230000001404 mediated effect Effects 0.000 title claims 3
- 230000003993 interaction Effects 0.000 title claims 2
- 150000008371 chromenes Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 239000000126 substance Substances 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Claims (9)
1. Tvar formule I
[image]
ili njena sol, pri čemu
svaki R1 nezavisno predstavlja vodik, C1-4 alkil, C2-4 alkenil, C2-4alkinil, hidroksil, C1-4alkoksil, C1-4alkoksiC1-4alkil, halo C1-4alkil, hidroksiC1-4alkil, cijanoC1-4alkil, halogen, -CN, NO2 ili Cy2;
R2 predstavlja vodik;
svaki R3 nezavisno predstavlja C1-4 alkil halo C1-4alkil ili halogen;
Cy1 predstavlja monociklički heterocikl od 5 ili 6 članova, zasićen ili djelomično nezasićen koji je pričvršćen za ostatak molekule preko bilo kojeg dostupnog N atoma, pri čemu Cy1 može sadržavati 1 ili 2 heteroatoma odabrana između N, O i S, pri čemu jedan ili više C ili S atoma iz prstena može biti oksidirano tako da tvori grupe CO, SO ili SO2, i gdje je Cy1 opcionalno supstituiran s jednim ili više R4;
svaki Cy2 nezavisno predstavlja aromatski prsten od 5-7 članova koji mogu biti pridruženi ostatku molekule preko bilo kojeg dostupnog C ili N atoma, gdje Cy2 može opcionalno biti udružen u prsten sa 5 ili 6 članova koji je karbociklički ili heterociklički zasićen, djelomično nezasićen ili aromatski, pri čemu Cy2 može ukupno sadržavati od 1 do 4 heteroatoma odabrana između N, O i S, pri čemu jedan ili više atoma C ili S iz prstena može biti oksidirano tako da tvori grupe CO, SO ili SO2, i gdje je Cy2 opcionalno supstituiran s jednim ili više R4;
svaki R4 nezavisno predstavlja, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, hidroksil, C1-4alkoksil, C1-4alkoksiC1-4alkil, halo C1-4alkil, hidroksiC1-4alkil, cijanoC1-4alkil, halogen, -CN ili NO2;
n predstavlja od 0 do 4; i
m predstavlja 1.
2. Tvar u skladu s patentnim zahtjevom 1 pri čemu svaki R1 nezavisno predstavlja vodik, C1-4alkoksil ili Cy2.
3. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 ili 2 pri čemu Cy1 predstavlja grupu:
[image]
4. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 3 gdje svaki Cy2 nezavisno predstavlja fenil ili aromatski prsten od 5 ili 6 članova koji može biti pridružen ostatku molekule preko bilo kojeg dostupnog C ili N atomom, gdje Cy2 sadrži 1 ili 2 heteroatoma odabrana između N, O i S, gdje jedan ili više atoma C ili S iz prstena može biti oksidirano tako da tvori CO, SO ili SO2 grupe, i gdje je Cy2 opcionalno supstituiran s jednim ili više R4.
5. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 4 gdje svaki R4 nezavisno predstavlja C1-4alkil, hidroksil, C1-4alkoksil, haloC1-4alkil, hidroksiC1-4alkil ili halogen.
6. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 5 gdje n predstavlja 0 ili 1.
7. Farmaceutski sastav obuhvaća tvar formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili njenu farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih ekscipijenasa.
8. Tvar formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili njena farmaceutski prihvatljiva sol za uporabu u liječenju bolesti posredovane međudjelovanjem TRC-Nck u T-limfocitima, pri čemu je bolest odabrana između odbacivanja transplantata, reumatoidnog artritisa, psorijatičnog artritisa, psorijaze, dijabetesa tipa I, komplikacija dijabetesa, multiple skleroze, sustavnog eritemskog lupusa, atopijskog dermatitisa, alergijskih reakcija posredovanih mast stanicama, leukemija, limfoma i tromboembolijskih i alergijskih komplikacija povezanih s leukemijama i limfomima.
9. Postupak za pripremu tvari formule I u skladu s patentnim zahtjevom 1, obuhvaća:
a) reagiranje tvari formule II s tvari formule III
[image]
gdje R1, R2, R3, Cy1, n i m imaju značenje opisano u patentnom zahtjevu 1; i/ili
b) transformiranje, u jednom od nekoliko stupnjeva, tvari formule I u drugu tvar formule I.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031437A ES2379242B1 (es) | 2010-09-28 | 2010-09-28 | Derivados de cromeno. |
| PCT/ES2011/070506 WO2012042078A1 (es) | 2010-09-28 | 2011-07-08 | Derivados de cromeno |
| EP11828172.4A EP2623503B1 (en) | 2010-09-28 | 2011-07-08 | Chromene derivatives useful in the treatment of a disease mediated by the tcr-nck interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151378T1 true HRP20151378T1 (hr) | 2016-01-15 |
Family
ID=45892008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151378TT HRP20151378T1 (hr) | 2010-09-28 | 2015-12-15 | Derivati kromena korisni u liječenju bolesti posredovane međudjelovanjem trc-nck |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9120764B2 (hr) |
| EP (1) | EP2623503B1 (hr) |
| JP (1) | JP5894164B2 (hr) |
| KR (1) | KR101800919B1 (hr) |
| CN (1) | CN103189367B (hr) |
| AU (1) | AU2011310078B2 (hr) |
| BR (1) | BR112013007073B1 (hr) |
| CA (1) | CA2813144C (hr) |
| DK (1) | DK2623503T3 (hr) |
| ES (1) | ES2379242B1 (hr) |
| HK (1) | HK1186727A1 (hr) |
| HR (1) | HRP20151378T1 (hr) |
| HU (1) | HUE025731T2 (hr) |
| MX (1) | MX342960B (hr) |
| PL (1) | PL2623503T3 (hr) |
| PT (1) | PT2623503E (hr) |
| WO (1) | WO2012042078A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201602982YA (en) * | 2013-10-17 | 2016-05-30 | Abbvie Deutschland | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| ES2534336B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| ES2534318B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| CN117304157A (zh) * | 2018-02-27 | 2023-12-29 | 阿塔克斯生物制药有限公司 | 作为tcr-nck相互作用的抑制剂的色烯衍生物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002008217A2 (en) * | 2000-07-21 | 2002-01-31 | Chugai Seiyaku Kabushiki Kaisha | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| BRPI0417543A (pt) * | 2003-12-12 | 2007-03-27 | Wyeth Corp | quinolinas úteis no tratamento de doença cardiovascular |
| WO2008005572A2 (en) * | 2006-07-06 | 2008-01-10 | Cytovia, Inc. | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
| ES2331451B1 (es) | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| BRPI0922135B1 (pt) * | 2008-12-05 | 2021-07-13 | Astellas Pharma Inc | Composto de 2h-cromeno ou um sal do mesmo, composição farmacêutica compreendendo dito composto e uso do mesmo para prevenir ou tratar uma doença induzida por infiltração de linfócito indesejável associada com s1p1 |
-
2010
- 2010-09-28 ES ES201031437A patent/ES2379242B1/es active Active
-
2011
- 2011-07-08 WO PCT/ES2011/070506 patent/WO2012042078A1/es active Application Filing
- 2011-07-08 KR KR1020137009083A patent/KR101800919B1/ko active IP Right Grant
- 2011-07-08 CN CN201180052704.8A patent/CN103189367B/zh active Active
- 2011-07-08 PT PT118281724T patent/PT2623503E/pt unknown
- 2011-07-08 CA CA2813144A patent/CA2813144C/en active Active
- 2011-07-08 AU AU2011310078A patent/AU2011310078B2/en active Active
- 2011-07-08 JP JP2013529685A patent/JP5894164B2/ja active Active
- 2011-07-08 DK DK11828172.4T patent/DK2623503T3/en active
- 2011-07-08 EP EP11828172.4A patent/EP2623503B1/en active Active
- 2011-07-08 US US13/824,178 patent/US9120764B2/en active Active
- 2011-07-08 BR BR112013007073-0A patent/BR112013007073B1/pt active IP Right Grant
- 2011-07-08 MX MX2013003498A patent/MX342960B/es active IP Right Grant
- 2011-07-08 HU HUE11828172A patent/HUE025731T2/en unknown
- 2011-07-08 PL PL11828172T patent/PL2623503T3/pl unknown
-
2013
- 2013-12-19 HK HK13114108.5A patent/HK1186727A1/zh unknown
-
2015
- 2015-12-15 HR HRP20151378TT patent/HRP20151378T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE025731T2 (en) | 2016-05-30 |
| HK1186727A1 (zh) | 2014-07-04 |
| AU2011310078A1 (en) | 2013-04-11 |
| CN103189367A (zh) | 2013-07-03 |
| RU2013117924A (ru) | 2014-11-10 |
| JP2013537899A (ja) | 2013-10-07 |
| US20140005247A1 (en) | 2014-01-02 |
| CA2813144C (en) | 2018-10-30 |
| CA2813144A1 (en) | 2012-04-05 |
| MX2013003498A (es) | 2013-05-20 |
| BR112013007073B1 (pt) | 2021-11-16 |
| PL2623503T3 (pl) | 2016-04-29 |
| BR112013007073A2 (pt) | 2020-04-28 |
| ES2379242B1 (es) | 2013-03-04 |
| AU2011310078B2 (en) | 2016-12-15 |
| ES2379242A1 (es) | 2012-04-24 |
| DK2623503T3 (en) | 2016-01-11 |
| KR101800919B1 (ko) | 2017-11-23 |
| JP5894164B2 (ja) | 2016-03-23 |
| EP2623503A4 (en) | 2014-03-05 |
| WO2012042078A1 (es) | 2012-04-05 |
| KR20130141481A (ko) | 2013-12-26 |
| EP2623503B1 (en) | 2015-09-23 |
| EP2623503A1 (en) | 2013-08-07 |
| CN103189367B (zh) | 2016-06-08 |
| PT2623503E (pt) | 2016-01-26 |
| US9120764B2 (en) | 2015-09-01 |
| MX342960B (es) | 2016-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151378T1 (hr) | Derivati kromena korisni u liječenju bolesti posredovane međudjelovanjem trc-nck | |
| Abhale et al. | Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives | |
| MA35903B1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HRP20150543T1 (hr) | Međuprodukti za pripravu halikondrina b | |
| HRP20110237T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| FR3037957B1 (fr) | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HRP20171425T1 (hr) | Derivati oksazolidin-2-on-pirimidina | |
| ATE541572T1 (de) | Tetrahydro-naphtalinderviate als glucocorticoidrezeptor-modulatoren | |
| AR078733A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de orexina | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| RS54124B1 (en) | COMPOSITIONS AND PROCEDURES FOR TREATMENT OF COLITIS | |
| JP2013531031A5 (hr) | ||
| HRP20080227T3 (hr) | Pirolidinski derivati kao ligandi histaminskih receptora | |
| AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
| CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
| AR075523A1 (es) | 4-metilbencenosulfonato de 6-metil-5-(1-metil-1h-pirazol-5-il)-n-[[5-(metilsulfonil)piridin-2-il]metil]-2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida y modificacion cristalina del mismo, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de enfer | |
| RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
| MA32570B1 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| ATE513546T1 (de) | Imidazolidin-derivate, ihre verwendungen, ihre zubereitung und diese enthaltende zusammensetzungen | |
| UY31141A1 (es) | Compuestos de piperidina y sus usos | |
| ECSP10010659A (es) | Derivados heterocíclicos de la urea y sus métodos de empleo | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| CN105646394B (zh) | 蒎烷基噻唑衍生物及其合成方法和应用 |